Recent News

• 05.28.2026 - Editas Medicine Announces Updated Presentation Time for Upcoming Investor Conference
• 05.26.2026 - Editas Medicine Announces Pricing of Up to $319.4 Million Public Offering
• 05.26.2026 - Editas Medicine Announces Proposed Public Offering
• 05.26.2026 - Editas Medicine Presents EDIT-401 Preclinical Data Demonstrating Robust Reductions in LDL-C, Lp(a), and ApoB in Non-Human Primates at the 94th European Atherosclerosis Society Congress
• 05.14.2026 - Editas Medicine Reports New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at the American Society of Gene and Cell Therapy 2026 Annual Meeting
• 04.27.2026 - Editas Medicine to Present New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at Upcoming Scientific Conferences

Recent Filings

• 05.26.2026 - 424B5 Prospectus [Rule 424(b)(5)]
• 05.26.2026 - 424B5 Prospectus [Rule 424(b)(5)]
• 05.26.2026 - EX-99.1 EX-99.1
• 05.26.2026 - EX-99.1 EX-99.1
• 05.26.2026 - 8-K Current report
• 05.26.2026 - 8-K Current report
• 05.26.2026 - S-3MEF Registration adding securities to prior Form S-3 registration [Rule 462(b)]
• 05.26.2026 - 8-K Current report
• 05.14.2026 - 8-K Current report
• 05.05.2026 - 8-K Current report